In December 2021, we entered into a multi-year, strategic collaboration with Roche and Genentech in key areas of neuroscience and an oncology indication. Through the partnership, we are working with both Roche and Genentech's R&D units to leverage the Recursion OS and Maps of Biology, along with extensive single-cell perturbation screening data from Roche and Genentech, to rapidly identify novel biological relationships to initiate and advance therapeutic programs.
For a behind-the-scenes look at the structure and progress of this expansive partnership, watch the video below and read more on Genentech's "Beyond the Deal" blog series.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Recursion Pharmaceuticals Inc. published this content on 23 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2022 21:54:00 UTC.